0001477932-18-004085.txt : 20180815 0001477932-18-004085.hdr.sgml : 20180815 20180815153104 ACCESSION NUMBER: 0001477932-18-004085 CONFORMED SUBMISSION TYPE: NT 10-Q PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180630 FILED AS OF DATE: 20180815 DATE AS OF CHANGE: 20180815 EFFECTIVENESS DATE: 20180815 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cure Pharmaceutical Holding Corp. CENTRAL INDEX KEY: 0001643301 STANDARD INDUSTRIAL CLASSIFICATION: PLASTICS, FOIL & COATED PAPER BAGS [2673] IRS NUMBER: 371765151 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NT 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55908 FILM NUMBER: 181020873 BUSINESS ADDRESS: STREET 1: 1620 BEACON PLACE CITY: OXNARD STATE: CA ZIP: 93033 BUSINESS PHONE: 805-824-0410 MAIL ADDRESS: STREET 1: 1620 BEACON PLACE CITY: OXNARD STATE: CA ZIP: 93033 FORMER COMPANY: FORMER CONFORMED NAME: Makkanotti Group Corp. DATE OF NAME CHANGE: 20150526 NT 10-Q 1 curr_nt10q.htm NT 10-Q curr_nt10q.htm

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 12b-25

 

Commission File Number 333-204857

 

NOTIFICATION OF LATE FILING

 

 

¨ Form 10-K

¨ Form 11-K

¨ Form 20-F

x Form 10-Q

¨ Form N-SAR

  

For Period Ended: June 30, 2018                              

 

¨ Transition Report on Form 10-K

¨ Transition Report on Form 10-Q

¨ Transition Report on Form 20-F

¨ Transition Report on Form N-SAR

 

For the Transition Period Ended: _____________________

 

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates: _____________________________

 

PART I

REGISTRANT INFORMATION

 

Full name of registrant

CURE Pharmaceutical Holding Corp.

 

Former name if applicable

Address of principal executive office

1620 Beacon Place

City, state and zip code

Oxnard, California 93033

 

 
 
 
 

 PART II

RULE 12b-25 (b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should be completed. (Check box if appropriate.)

 

 

x

 

 

(a)

The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

 

 

 

 

(b)

The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form 10-Q, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

 

 

 

 

(c)

The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III

NARRATIVE

 

State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR or the transition report portion thereof could not be filed within the prescribed time period.

 

The registrant is in the process of preparing and reviewing the financial information of the Company. The process of compiling and disseminating the information required to be included in the Form 10-Q, could not be completed without incurring undue hardship and expense.

 

PART IV

OTHER INFORMATION

 

(1)

Name and telephone number of person to contact in regard to this notification

 

Robert Davidson

 

(805)

 

824-0410

(Name)

 

(Area Code)

 

(Telephone Number)

 

(2)

Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). x Yes   ¨ No

 

(3)

Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ¨ Yes   x No

 

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

 

2

 
 

  

CURE Pharmaceutical Holding Corp.

Name of Registrant as Specified in Charter.

 

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: August 15, 2018

By:

/s/ Robert Davidson

Name:

Robert Davidson

Title:

Chief Executive Officer

 

 

3